Maven Clinic, Chery Holding, and Brazil Potash Corp are each preparing for IPOs. Maven Clinic, a women’s telehealth service, appoints a new CFO for growth ahead of its planned U.S. IPO. China’s Chery Holding eyes a $14 billion Hong Kong IPO. Brazil Potash targets a $77 million U.S. IPO to support potash mining.

IPOX® Research Analyst Dr. Lukas Muehlbauer commented on Septerna's upsized U.S. IPO as the Goldman Sachs-backed drug developer targets a valuation of $743.1 million. Septerna, originally planning to offer 10.9 million shares within a $15-$17 range, has now increased its offering to 15.3 million shares, pricing them at $18 each, to raise approximately $275 million. This move reflects positive investor sentiment for biotech IPOs, which have seen strong performances in the U.S. market this fall.

Global IPO activity is surging: Hyundai Motor India's $3.3 billion offering, the largest in India's history, achieved 18% subscription on day one. Oman's OQ Exploration raised a record $2.03 billion in the country's biggest IPO. UAE's Lulu Group plans a $1.8 billion IPO in Abu Dhabi. Tokyo Metro is setting up a significant listing in Japan. Horizon Robotics, backed by Alibaba and Baidu, launches a $696 million Hong Kong IPO. Pony.ai seeks $300 million in a U.S. IPO.

In a recent Reuters article, IPOX® CEO Dr. Josef Schuster highlighted the strategic timing behind Ingram Micro's return to the U.S. stock market, as the global technology distributor seeks a valuation of up to $5.42 billion. Schuster emphasized that private equity firms, like Ingram's backer Platinum Equity, are capitalizing on favorable market conditions, strong demand, and the opportunity to monetize their investments.

Honeywell plans to spin off its advanced materials division, generating $3.7-$3.9 billion in revenue, into a new public company by 2026. Cerebras Systems is likely to delay its IPO due to a CFIUS review over foreign investment. Tokyo Metro's $2.35 billion IPO is multiple times oversubscribed internationally and will begin trading on October 23, 2024. TenneT explores a spin-off or stake sale of its $21.95 billion German unit.

In a recent Reuters article, IPOX® Research Analyst Dr. Lukas Muehlbauer discussed the strong debut of Upstream Bio (UPB.O) in the IPO market. The Waltham, Massachusetts-based drug developer saw its stock rise 26.5% above the IPO price, giving it a market value of $1.05 billion.

Several high-profile IPOs are set to debut across global markets. AI chipmaker Cerebras Systems plans a major Nasdaq listing, while Brazilian fintech PicPay and digital lender K Bank target significant offerings in 2025. In Europe, payments firm Ebury and sports supplements company Applied Nutrition prepare for London IPOs. Chinese AI firm Horizon Robotics seeks to raise $500 million in Hong Kong, and food delivery giant Talabat is eyeing a blockbuster Dubai listing with a potential valuation up to $15.1 billion.

Major upcoming IPOs include Titan America's expected $500 million raise in early 2025, potentially valuing it over $2 billion, and Spring Nature's anticipated IPO, possibly valuing the company at $10 billion by late 2024. In Asia, Midea Group raised $3.98 billion in Hong Kong's largest IPO in four years, while Enflame Technology aims to raise $280 million, targeting Shanghai's STAR board in late 2024.

Major upcoming IPOs include Titan America's expected $500 million raise in early 2025, potentially valuing it over $2 billion, and Spring Nature's anticipated IPO, possibly valuing the company at $10 billion by late 2024. In Asia, Midea Group raised $3.98 billion in Hong Kong's largest IPO in four years, while Enflame Technology aims to raise $280 million, targeting Shanghai's STAR board in late 2024.